Core Viewpoint - Rosen Law Firm is reminding investors who purchased DexCom, Inc. securities between July 26, 2024, and September 17, 2025, of the upcoming lead plaintiff deadline on December 29, 2025, for a class action lawsuit related to misleading statements made by the company [1]. Group 1: Class Action Details - Investors who purchased DexCom securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To participate in the class action, investors can submit their information through the provided link or contact the law firm directly [3][6]. - A lead plaintiff must file a motion with the Court by December 29, 2025, to represent other class members in the litigation [3]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting their own achievements in recovering hundreds of millions for investors [4]. - The firm has been recognized for its performance in securities class action settlements, including being ranked No. 1 for the number of settlements in 2017 and consistently in the top 4 since 2013 [4]. Group 3: Case Allegations - The lawsuit alleges that DexCom made unauthorized design changes to its G6 and G7 continuous glucose monitoring systems, which compromised their reliability and posed health risks to users [5]. - It is claimed that the company overstated the enhancements and reliability of the G7 devices while downplaying the severity of the issues, leading to increased regulatory scrutiny and potential legal repercussions [5].

Core Viewpoint - DexCom, Inc. is facing a lawsuit for alleged violations of securities laws, which may impact its financial standing and investor confidence [1] Company Summary - The lawsuit has been filed against DexCom, Inc. by the DJS Law Group, indicating potential legal challenges for the company [1] - The nature of the allegations suggests that there may be significant implications for the company's compliance with securities regulations [1] Industry Summary - The case highlights ongoing scrutiny within the healthcare technology sector, particularly regarding companies involved in diabetes management and monitoring solutions [1] - Legal actions like this can affect market perceptions and valuations of companies in the healthcare technology industry [1]

Core Viewpoint - A class action securities lawsuit has been filed against DexCom, Inc. alleging securities fraud that affected shareholders between January 8, 2024, and September 17, 2025 [2]. Group 1: Lawsuit Details - The lawsuit claims that DexCom made false statements and concealed material design changes to its glucose monitoring products, the G6 and G7, which were unauthorized by the U.S. Food and Drug Administration [3]. - It is alleged that these design changes made the G6 and G7 less reliable, posing a material health risk to users who depend on these devices for accurate glucose readings [3]. - The complaint asserts that the enhancements to the G7, along with its reliability, accuracy, and functionality, were overstated, and the true scope of the issues was downplayed [3]. Group 2: Implications - The alleged actions have subjected DexCom to increased regulatory scrutiny and potential enforcement actions, leading to significant legal, reputational, and financial harm [3]. - The public statements made by the defendants are claimed to have been materially false and misleading throughout the relevant period [3]. Group 3: Next Steps for Affected Shareholders - Shareholders who suffered losses during the specified timeframe are encouraged to seek information about their rights to recovery, with no cost or obligation to participate [4]. Group 4: Legal Representation - Levi & Korsinsky LLP, a recognized securities litigation firm, has a history of securing substantial recoveries for shareholders and has been ranked among the top securities litigation firms in the U.S. for seven consecutive years [5].

Company Overview - DexCom, Inc. (DXCM) is a leading medical-device company specializing in continuous glucose monitoring (CGM) systems for diabetes management, with a market capitalization of approximately $23.2 billion [1] Stock Performance - Over the past 52 weeks, DXCM stock has declined by 19.8%, while the S&P 500 Index has increased by 14.5%. Year-to-date, the stock is down 23.4%, compared to a 16.5% rise in the S&P 500 [2] - DexCom's shares have also underperformed the Health Care Select Sector SPDR Fund, which returned 3.8% over the past 52 weeks and 11.1% year-to-date [3] Earnings and Outlook - The company reported a solid third-quarter earnings performance, beating estimates; however, management's outlook indicated that growth in 2026 may be slightly below market expectations, raising concerns among investors [4] - For the fiscal year ending December 2025, analysts project DexCom's earnings per share (EPS) to grow by 26.2% year-over-year to $2.07. The company's earnings surprise history is mixed, with two beats and two misses in the last four quarters [5] Analyst Ratings - Among 28 analysts covering DexCom, the consensus rating is a "Strong Buy," consisting of 21 "Strong Buys," one "Moderate Buy," and six "Hold" ratings [6] - The consensus rating has become slightly more bullish compared to three months ago, when there were 20 "Strong Buy" ratings [7] Price Targets - Bernstein SocGen Group recently lowered its price target for DexCom from $98 to $84 while maintaining an "Outperform" rating. The mean price target of $87.38 suggests a potential upside of 46.7% from current levels, while the highest target of $125 indicates a possible rally of 109.7% [7]

Core Viewpoint - Rosen Law Firm is encouraging investors of DexCom, Inc. to secure legal counsel before the December 29, 2025 deadline for a class action lawsuit related to securities purchased between July 26, 2024, and September 17, 2025 [2][3]. Group 1: Class Action Details - Investors who purchased DexCom securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [3]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by December 29, 2025 [4]. - The Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [5]. Group 2: Allegations Against DexCom - The lawsuit alleges that DexCom made unauthorized material design changes to its G6 and G7 continuous glucose monitoring systems, which compromised their reliability and posed health risks to users [6]. - It is claimed that DexCom overstated the enhancements and reliability of the G7 devices while downplaying the severity of the issues related to the adulterated devices [6]. - The allegations suggest that these misrepresentations subjected DexCom to increased regulatory scrutiny and potential legal and financial repercussions [6].

Core Viewpoint - Securities class action lawsuits have been filed against DexCom, Inc. for alleged misleading statements and undisclosed risks related to its continuous glucose monitoring systems during the specified class period from January 8, 2024, to September 17, 2025 [1][2]. Group 1: Allegations Against DexCom - Defendants allegedly made false or misleading statements regarding unauthorized design changes to the G6 and G7 glucose monitoring systems, which compromised their reliability and posed health risks to users [2]. - The enhancements claimed for the G7 device were reportedly overstated, and the company downplayed the severity of issues related to the G7 devices [2]. - The alleged misconduct has led to increased regulatory scrutiny and potential legal, reputational, and financial harm for DexCom [2]. Group 2: Legal Process for Investors - Investors in DexCom can seek to be appointed as lead plaintiffs by December 26, 2025, or remain absent class members [3]. - The lead plaintiff will represent the interests of all class members and select legal counsel for the case [3]. - Participation as a lead plaintiff does not affect the ability of investors to share in any recovery from the lawsuit [3].

Core Viewpoint - DexCom's stock has declined by 25% since the beginning of 2025, despite a generally positive stock market environment, raising questions about its future performance and potential buying opportunities [1][2]. Financial Performance - DexCom reported third-quarter earnings on October 30, with revenue of $1.2 billion, reflecting a year-over-year increase of 22%. However, this growth is compared to a period of slow growth last year, leading to skepticism among investors regarding its sustainability [4]. Market Concerns - Investors are increasingly bearish on DexCom due to the emergence of GLP-1 weight loss drugs, which may reduce the demand for continuous glucose monitoring (CGM) devices. These drugs have shown effectiveness in lowering glucose levels for diabetes patients, potentially impacting DexCom's market [5][6]. Stock Valuation - DexCom's stock is currently trading at levels not seen since the COVID-19 crash of 2020, with a forward price-to-earnings (P/E) multiple of 26, which is lower than its historical average. This situation may present a buying opportunity for investors [7][8].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased DexCom, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased DexCom securities between July 26, 2024, and September 17, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by December 29, 2025 [3]. - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [6]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4]. - The firm has secured significant settlements for investors, including over $438 million in 2019 alone, and has been consistently ranked among the top firms for securities class action settlements [4]. Group 3: Case Allegations - The lawsuit alleges that DexCom made unauthorized design changes to its G6 and G7 continuous glucose monitoring systems, which compromised their reliability and posed health risks to users [5]. - It is claimed that the company downplayed the severity of issues related to the G7 devices, leading to increased regulatory scrutiny and potential legal repercussions [5]. - The lawsuit asserts that the public statements made by DexCom were materially false and misleading, resulting in investor damages when the true information became public [5].

Core Insights - Whales have adopted a bearish stance on DexCom, with 62% of trades being bearish and only 25% bullish [1] - The major market movers are focusing on a price band between $40.0 and $70.0 for DexCom over the last three months [2] - DexCom's options trading volume and open interest indicate significant liquidity and interest within the specified price range [3] Options Activity - A total of 8 trades were detected, with 2 puts amounting to $370,845 and 6 calls totaling $506,319 [1] - The largest options trades include bearish puts and calls, with notable trades at strike prices of $55.00 and $65.00 [8] - The current volume of options trading for DexCom is substantial, with a snapshot indicating significant activity [4][6] Company Overview - DexCom specializes in continuous glucose monitoring systems for diabetic patients, providing an alternative to traditional blood glucose meters [9] - The company is evolving its systems to integrate with insulin pumps for automatic insulin delivery [9] Market Position - Professional analysts have set an average target price of $84.0 for DexCom, with individual targets ranging from $75.0 to $95.0 [10][11] - The current stock price of DXCM is $57.71, reflecting a 5.23% increase [13]

Core Insights - DexCom, Inc. (DXCM) is positioned for growth in the continuous glucose monitoring (CGM) market, with a strong third-quarter performance and favorable coverage decisions expected to drive further growth, despite facing stiff competition [1][2] Company Overview - DexCom has a market capitalization of $21.45 billion and projects a 22.5% growth rate over the next five years, indicating strong future performance [2] - The company has surpassed earnings estimates in two of the last four quarters, with an average surprise of 0.17% [2] CGM Market Potential - The diabetes market presents significant potential, with over 130 million people in the U.S. and more than 400 million globally affected by diabetes, driving demand for CGM devices [3] - The global CGM device market is expected to grow at a CAGR of nearly 10%, reaching $14 billion by 2032 from over $6 billion currently [4] Product Ecosystem and Innovation - DexCom generates nearly 90% of its revenue from disposable CGM sensors, with strong demand driven by product performance and user experience [6] - The G7 and One+ products are gaining traction due to broader insurance coverage and growing physician support, particularly among Type 2 diabetes patients [6] - DexCom's software ecosystem, including features like AI-powered insights, is enhancing patient engagement and supporting reimbursement efforts [7] Recent Developments - The launch of Stelo in 2024 has already generated over $100 million in its first year, indicating strong market acceptance [8] - DexCom is expanding global reimbursement for its CGM sensors, which is expected to drive broader adoption, especially among Type 2 diabetes patients [9] International Expansion - DexCom has made significant progress in international markets, securing reimbursements in countries like France, Canada, and Japan, which is expected to improve affordability and patient access [11] Financial Performance - DexCom reported strong third-quarter results with double-digit top-line growth and raised full-year guidance, reflecting successful execution in expanding access to CGM [12] - The Zacks Consensus Estimate for 2025 earnings per share has increased to $2.07, with fourth-quarter revenue expected to improve by 11.7% year over year [15]